Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: cardiffoncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $8.00 | Buy | Craig Hallum |
| 2/28/2022 | $26.00 → $25.00 | Buy | HC Wainwright & Co. |
| 1/5/2022 | Outperform | William Blair | |
| 12/8/2021 | $19.00 | Outperform | Robert W. Baird |
| 12/8/2021 | $19.00 | Outperform | Baird |
| 8/10/2021 | $25.00 → $26.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $20.00 | Buy | Maxim Group |
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) for the treatment of KRAS mutated metastatic colorectal cancer (mCRC) patients who have
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2024. "This quarter has be
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients - - Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC - - Initial readout from first-line RAS-mutant mCRC CRDF-004 trial expected in H2 2024 - SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company lev
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carcinomas - - Five abstracts presented at AACR provide strong scientific rationale for the clinical development of onvansertib across multiple tumor types and various combinations - - Cash and equivalents of $60 million as of June 30, 2024, projected runway through the end of Q3 2025 - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-s
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on Thursday, August 8 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on August 8, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-event
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024. Details of the presentations can be found below. Presenters: Mark Erlander, CEODate: June 5, 2024Time: 8:30 – 8:55 AM ET in Track 8 Interested parties can register for and access the live webcasts for these conferences by visiting the "Events" section of the Cardif
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below. H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQLocation: The Nasdaq Headquarters, New York CityPresenter: Mark Erlander, CEOFormat: Fireside ChatDate: 05/20/2024Time: 2:30 PM ET Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHALocation: VirtualPresenter: Mark Erlander, CEOFormat: Fireside ChatDate: 05
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib's antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib's activity in combination treatments - - Cash and equivalents of $67 million as of March 31, 2024, projected runway into Q3 2025 - - Company will hold a conference call today at 4:30 p.m.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC – Therapeutic areas outside of RAS-mutated mCRC – In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combin
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)
S-8 - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
DEFA14A - Cardiff Oncology, Inc. (0001213037) (Filer)
DEFA14A - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously
William Blair initiated coverage of Cardiff Oncology with a rating of Outperform
Robert W. Baird initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $19.00
Baird initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $19.00
HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $26.00 from $25.00 previously
Maxim Group resumed coverage of Cardiff Oncology with a rating of Buy and set a new price target of $20.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $27.00 previously
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2024. "This quarter has be
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carcinomas - - Five abstracts presented at AACR provide strong scientific rationale for the clinical development of onvansertib across multiple tumor types and various combinations - - Cash and equivalents of $60 million as of June 30, 2024, projected runway through the end of Q3 2025 - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-s
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on Thursday, August 8 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on August 8, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-event
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib's antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib's activity in combination treatments - - Cash and equivalents of $67 million as of March 31, 2024, projected runway into Q3 2025 - - Company will hold a conference call today at 4:30 p.m.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Cash and equivalents of $75 million as of December 31, 2023, projected runway into Q3 2025 - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company discontinued the ONSEMBLE trial in August 2023 to shift focus of clinical development program to first-line RAS-mutated mCRC in agreement with the FDA - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today provided a clinical update on the first release of data
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial topline results expected in mid-2024 – - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the first patient was dosed in its randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated metastatic colorectal cancer (m
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024. Individuals interested in listening to the live conference call may do so by usin
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs. 7.7%) and mPFS of 5.0 months (vs. 3.1 months) - - Pancreatic cancer biomarker discovery trial in refractory patients demonstrated tumor biomarker response to onvansertib treatment as a single-agent - - Based on positive data from both pancreatic trials and supportive preclinical data, a first-line pancreatic investigator-initiated trial is planned to evaluate the efficacy of onvansertib + SoC - Small Cell Lung Cancer Program - Preliminary data from small cell lung cancer Phase 2 trial in refractory patients with
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q
Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director. Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company's pre-clinical and clinical drug development programs and associated intellectual property. Dr. Thomas H. Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the Universit
SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. Rodney Markin has been appointed by the Board of Directors as the Company's new Chairman of the Board. "On behalf of the entire Board, I would like to thank Tom for his
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.
Gainers Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 41.17% to $0.15. The company's market cap stands at $18.6 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 28.37% to $0.38. The market value of their outstanding shares is at $108.1 million. Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 19.56% to $1.47. The company's market cap stands at $6.8 million. Ardelyx (NASDAQ:ARDX) stock increased by 16.64% to $7.92. The company's market cap stands at $1.8 billion. As per the news, the Q1 earnings report came out ye
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 12 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $205.000 thousand which beat the analyst consensus estimate of $55.000 thousand by 272.73 percent. This is a 146.99 percent increase over sales of $83.000 thousand the same period last year.
Gainers Twist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out today. Jaguar Health (NASDAQ:JAGX) shares increased by 13.91% to $0.33. The company's market cap stands at $95.9 million. Tandem Diabetes Care (NASDAQ:TNDM) stock moved upwards by 12.25% to $41.04. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out today. Indaptus Therapeutics (NASDAQ:INDP) stock moved upwards by 11.29% to $2.26. The company's market cap stands at $19.2 million. Ardelyx (NASDAQ:ARDX) shares rose 11.02% to $7.54. Th
– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth –– Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC –Therapeutic areas outside of RAS-mutated mCRC– In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighti
Gainers Heron Therapeutics (NASDAQ:HRTX) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings came out yesterday. TRACON Pharma (NASDAQ:TCON) stock rose 34.56% to $0.52. The market value of their outstanding shares is at $23.8 million. NuCana (NASDAQ:NCNA) stock rose 34.32% to $0.52. The company's market cap stands at $27.2 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 33.01% to $0.11. The market value of their outstanding shares is at $4.3 million. Cardiff Oncology (NASDAQ:CRDF) shares increased by 27.9% to $5.73. The company's market cap stands at $256.0 millio
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $12 to $14.
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dropping, 0.01% to 5,137.05. Check This Out: Top 4 Tech Stocks That May Implode This Month Leading and Lagging Sectors Utilities shares rose by 0.9% on Monday. In trading on Monday, communication services shares fell by 1.6%. Top Headline Super Micro Computer, Inc. (NASDAQ:SMCI) will join the S&P 500 Index, effective March 18, S&P Dow Jones Indices, a division of S&P Global, said in a release. Deckers Outdoor Corporation (NASDAQ:DECK) will replace Zions Bancorporation (NASDAQ:ZI
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13D/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)